Title |
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients The ROADMAP Study 2-Year Results
|
---|---|
Published in |
JACC: Heart Failure, April 2017
|
DOI | 10.1016/j.jchf.2017.02.016 |
Pubmed ID | |
Authors |
Randall C. Starling, Jerry D. Estep, Douglas A. Horstmanshof, Carmelo A. Milano, Josef Stehlik, Keyur B. Shah, Brian A. Bruckner, Sangjin Lee, James W. Long, Craig H. Selzman, Vigneshwar Kasirajan, Donald C. Haas, Andrew J. Boyle, Joyce Chuang, David J. Farrar, Joseph G. Rogers, ROADMAP Study Investigators |
Abstract |
The authors sought to provide the pre-specified primary endpoint of the ROADMAP (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients) trial at 2 years. The ROADMAP trial was a prospective nonrandomized observational study of 200 patients (97 with a left ventricular assist device [LVAD], 103 on optimal medical management [OMM]) that showed that survival with improved functional status at 1 year was better with LVADs compared with OMM in a patient population of ambulatory New York Heart Association functional class IIIb/IV patients. The primary composite endpoint was survival on original therapy with improvement in 6-min walk distance ≥75 m. Patients receiving LVAD versus OMM had lower baseline health-related quality of life, reduced Seattle Heart Failure Model 1-year survival (78% vs. 84%; p = 0.012) predominantly INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile 4 (65% vs. 34%; p < 0.001) versus profiles 5 to 7. More LVAD patients met the primary endpoint at 2 years: 30% LVAD versus 12% OMM (odds ratio 3.2 [95% confidence interval 1.3 to 7.7]; p = 0.012). Survival as treated on original therapy at 2 years was greater for LVAD versus OMM (70 ± 5% vs. 41 ± 5%; p < 0.001), but there was no difference in intent-to-treat survival (70 ± 5% vs. 63 ± 5%; p = 0.307). In the OMM arm, 23 of 103 (22%) received delayed LVADs (18 within 12 months; 5 from 12 to 24 months). LVAD adverse events declined after year 1 for bleeding (primarily gastrointestinal) and arrhythmias. Survival on original therapy with improvement in 6-min walk distance was superior with LVAD compared with OMM at 2 years. Reduction in key adverse events beyond 1 year was observed in the LVAD group. The ROADMAP trial provides risk-benefit information to guide patient- and physician-shared decision making for elective LVAD therapy as a treatment for heart failure. (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients [ROADMAP]; NCT01452802). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 7 | 47% |
Argentina | 1 | 7% |
Brazil | 1 | 7% |
Unknown | 6 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 67% |
Practitioners (doctors, other healthcare professionals) | 2 | 13% |
Science communicators (journalists, bloggers, editors) | 2 | 13% |
Scientists | 1 | 7% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | <1% |
United States | 1 | <1% |
Unknown | 188 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 28 | 15% |
Student > Master | 21 | 11% |
Student > Bachelor | 21 | 11% |
Student > Postgraduate | 17 | 9% |
Other | 15 | 8% |
Other | 32 | 17% |
Unknown | 56 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 75 | 39% |
Nursing and Health Professions | 13 | 7% |
Engineering | 13 | 7% |
Computer Science | 5 | 3% |
Agricultural and Biological Sciences | 4 | 2% |
Other | 17 | 9% |
Unknown | 63 | 33% |